Journals / Annals of Medical Research / 2022 / Cilt: 29 - Sayı: 4

Bullous dermatosis in the southeastern of Turkey: A study of 125 cases

Pages
320–324
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Since our study is the first data obtained on bullous diseases from the southeastern Anatolia region, it is useful for the literature in terms of providing a basis for future studies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Autoimmune bullous diseases occur when antibodies against proteins such as desmosomes and hemidesmosomes cause separation in the skin.
📊
Key Findings & Data:Materials and Methods: The data of 125 cases who were followed up with a diagnosis of bullous disease between 2006 and 2019 were evaluated retrospectively.
💡
Conclusion & Impact:Conclusion: Since our study is the first data obtained on bullous diseases from the southeastern Anatolia region, it is useful for the literature in terms of providing a basis for future studies.
🔬Design:Research Article
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Autoimmune bullous diseases occur when antibodies against proteins such as desmosomes and hemidesmosomes cause separation in the skin. Detailed epidemiological studies examining these diseases are limited in our country. We aim to contribute to the demographic, clinical, and treatment data on bullous diseases from an important geographic region of our country. Materials and Methods: The data of 125 cases who were followed up with a diagnosis of bullous disease between 2006 and 2019 were evaluated retrospectively. Socio-demographic characteristics, diagnoses, age and duration of disease onset, clinical findings, accompanying systemic diseases, treatments given, and side effects related to treatment were recorded. Results: 57.6% of the patients (72 people) were diagnosed as pemphigus, 31.2% (39 people) bullous pemphigoid (BP), 8% (10 people) dermatitis herpetiformis (DH), 3.2% (4 people) linear Ig A dermatosis ( LAD). BP patients were found to be significantly older than the other patients (p = 0.002). While pemphigus, BP, and LAD were more common in women, 70% of DH patients were men. Malignancy was detected in 2.8% of pemphigus patients and 5.1% of BP patients. Accompanying autoimmune disease was found in 9.7% of pemphigus patients, 17.9% of BP patients, and 20% of DH patients. The only systemic steroid was used in 20.8% of pemphigus patients, and azathioprine as a conventional agent was used in 76.4% with systemic steroid. Rituximab was started in patients who did not respond to therapy. The systemic steroid was used in 35.9% of BP patients, and azathioprine with systemic steroid was used in 43.6% of BP patients. Doxycycline was added to the treatment in 41% of the patients. Rituximab was used in 5 (12.8%) patients. Conclusion: Since our study is the first data obtained on bullous diseases from the southeastern Anatolia region, it is useful for the literature in terms of providing a basis for future studies. İrem

🔖

Cite This Article

YANATMA, İ., SARAÇ, G., CENK, H., KARATOPRAK, H. V. (2022). Bullous dermatosis in the southeastern of Turkey: A study of 125 cases. Annals of Medical Research, Cilt: 29 - Sayı: 4, 320–324. https://ajindex.com/articles/445585

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Alpsoy E, Akman-Karakas A, Uzun S. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid. Archives of dermatological research 2015; 307: 291-8
  2. Uzun S, Durdu M, Akman A et al. Pemphigus in the Mediterranean region of Turkey: a study of 148 cases. International journal of dermatology 2006; 45: 523-8
  3. Daye M, Mevlitoğlu İ, Esener S. Konya ilinde büllöz hastalıklar: 93 olgu üzerine bir çalışma. Turkderm 2013; 47: 200-4
  4. Jung M, Kippes W, Messer G et al. Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. Journal of the American Academy of Dermatology 1999; 41: 266-8
  5. Marazza G, Pham HC, Schärer L et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. The British journal of dermatology 2009; 161: 861-8
  6. Bertram F, Bröcker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG 2009; 7: 434-40
  7. Mendes FB, Hissa-Elian A, Abreu MA, Gonçalves VS. Review: dermatitis herpetiformis. An Bras Dermatol 2013; 88: 594-9
  8. Parker SR, MacKelfresh J. Autoimmune blistering diseases in the elderly. Clinics in dermatology 2011; 29: 69-79
  9. Balestri R, Magnano M, La Placa M et al. Malignancies in bullous pemphigoid: a controversial association. The Journal of dermatology 2016; 43: 125-33
  10. Lindelöf B, Islam N, Eklund G, Åfors L. Pemphigoid and cancer. Archives of dermatology 1990; 126: 66-8
  11. Camisa C, Helm TN. Paraneoplastic pemphigus is a distinct neoplasia-induced autoimmune disease. Archives of dermatology 1993; 129: 883-6
  12. Ogawa H, Sakuma M, Morioka S et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci 1995; 9: 136-41
  13. Karabay EA, Çerman AA, Altunay İ K. Evaluation of Comorbidities in Patients with Autoimmune Bullous Diseases: A Retrospective Study. Sisli Etfal Hastanesi tip bulteni 2018; 52: 302- 6
  14. Caproni M, Cardinali C, Renzi D et al. Tissue transglutaminase antibody assessment in dermatitis herpetiformis. The British journal of dermatology 2001; 144: 196-7
  15. Alonso-Llamazares J, Gibson LE, Rogers RS, 3rd. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience. International jou